

# Emergence of Carbapenem-Hydrolyzing Oxacillinases in *Acinetobacter baumannii* in Children from Croatia

---

Lukić-Grić, Amarela; Kos, Matea; Žižek, Marta; Luxner, Josefa; Grisold, Andrea; Zarfel, Gernot; Bedenić, Branka

Source / Izvornik: **Chemotherapy, 2019, 64, 167 - 172**

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1159/000503746>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:293799>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2025-03-21**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine  
Digital Repository](#)



## **Emergence of carbapenem hydrolyzing oxacillinases in *Acinetobacter baumannii* in children from Croatia**

Amarela Lukić-Grlić<sup>1,2</sup>, Matea Kos<sup>2</sup>, Marta Žižek<sup>3</sup>, Josefa Luxner<sup>4</sup>, Andrea Grisold<sup>4</sup>, Gernot Zarfel<sup>4</sup>, Branka Bedenić<sup>1,5</sup>

<sup>1</sup> School of Medicine, University of Zagreb, Zagreb, Croatia

<sup>2</sup> Children's hospital Zagreb, Zagreb, Croatia

<sup>3</sup> Faculty of Health Sciences, University of Zagreb, Croatia

<sup>4</sup> Institute of Microbiology, Hygiene and Environmental Medicine, Medical University of Zagreb

<sup>5</sup> University Hospital Center, Zagreb, Croatia

Short Title: Carbapenem hydrolyzing oxacillinases in *Acinetobacter baumannii* in children

\*Corresponding Author

Amarela Lukić-Grlić

Department of clinical microbiology

Children's hospital Zagreb

Klaićeva 16

Zagreb, Croatia, 10000

Tel: 385 1 46 00 141

Fax: 385 1 48 26 053

E-mail: [amarela.lukic@kdb.hr](mailto:amarela.lukic@kdb.hr)

Key words: *Acinetobacter baumannii*, OXA-23-like, OXA-24-like, carbapenem resistance

## **Abstract**

**Introduction:** Carbapenem resistance in *Acinetobacter baumannii* can be mediated by carbapenemases of class A, class B metallo- $\beta$ -lactamases (MBLs) and class D carbapenem-hydrolyzing oxacillinases (CHDL). The aim of the study was to investigate the antimicrobial susceptibility and  $\beta$ -lactamase production of carbapenem-resistant *A.baumannii* isolates (CRAB) from Children's Hospital Zagreb, Croatia.

**Methods:** A total of 12 *A. baumannii* isolates collected between August 2016 and March 2018 were analyzed. Antibiotic susceptibility was determined by broth microdilution method. The presence of MBLs was explored by combined disk test with EDTA. The presence of carbapenemases of class A, B and D was explored by PCR. The occurrence of the *ISAbal* upstream of the *bla*<sub>OXA-51-like</sub> or *bla*<sub>OXA-23-like</sub> was determined by PCR mapping. Epidemiological typing was performed by determination of sequence groups (SG). Genotyping was performed by sequence group determination, rep-PCR and MLST.

**Results:** All CRAB were resistant to piperacillin/tazobactam, ceftazidime, cefotaxime, ceftriaxone, cefepime, imipenem, meropenem, gentamicin and ciprofloxacin. Moderate resistance rates were observed for ampicillin/sulbactam (67%) and tigecycline (42%). The isolates were uniformly susceptible to colistin. PCR revealed the presence of genes encoding OXA-24-like CHDL in nine and OXA-23-like CHDL in three isolates. *bla*<sub>OXA-51</sub> genes were preceded by *ISAbal*. PCR for the common MBLs in *Acinetobacter* was negative. All isolates belonged to SG 1 corresponding to ICL II. Rep-PCR identified four major clones.

**Conclusions:** The study found OXA-24-like beta-lactamase to be the dominant CHDL among children's CRAB. The predominant spread of OXA-24-like is in contrast with recent global dissemination of OXA-23 reported all over the world. In contrast to the previous studies in

which emergency of OXA-24-like positive isolates was monoclonal we found considerable genetic diversity of the isolates.

## **Introduction**

The emergence of carbapenem resistance in *Acinetobacter* spp is a significant public health concern leaving few therapeutic options remaining [1]. Carbapenem hydrolyzing oxacillinases belonging to molecular Ambler class D (CHDL) [2] have emerged globally as the main mechanism responsible for this resistance, although metallo- $\beta$ -lactamases are prevalent in some area, particularly Far East [3-5]. Class A carbapenemases (KPC) are rare in *Acinetobacter* spp [6]. Enzymes belonging to OXA-51 group are naturally occurring  $\beta$ -lactamases of *A. baumannii* and are normally expressed at low levels but can be overexpressed as a consequence of the IS*AbaI* located upstream of the *bla*<sub>OXA-51</sub> genes [7]. However, *Acinetobacter* may develop resistance to carbapenems through various combined mechanisms including decreased permeability, altered penicillin binding proteins (PBPs) and, rarely, efflux pump overexpression [7]. Our previous studies demonstrated that carbapenem resistance was rare in Croatia until 2002. The first carbapenem-resistant isolates in Croatia were found in the University Hospital Split in 2002 [8], followed by carbapenem-resistant *Acinetobacter* isolates found in multiple centers in Croatia [9-16]. The dominant type of CHDL in Split and Zagreb University hospitals was OXA-72 which is widespread in Balcan geographic region [10-11] with sporadic occurrence of OXA-23 and OXA-58.

In spite of the high number of publications concerning carbapenem-resistant *A. baumannii* in Croatia [9-16], there are no bibliographical references on the carbapenemases in *A. baumannii* in paediatric population. The aim of the present study was to analyze the resistance patterns and mechanisms of paediatric carbapenem-resistant *A. baumannii* (CRAB) isolates.

## **Material and methods**

## *Bacteria*

Between August 2016 and March 2018, 28 (72%) out of 39 *A.baumannii* isolates were resistant to carbapenems. A total of 12 CRAB isolates (single isolate from single patient) were analyzed. The isolates were collected in intensive care unit, burn unit, surgery, paediatric and orthopedic ward of the Children's hospital in Zagreb, Croatia from various clinical specimens. Ten isolates were obtained from infected patients and two from colonized patients. The isolates were identified by conventional biochemical testing and MALDI-TOF. The identification was confirmed by PCR for *bla*<sub>OXA-51</sub> gene. The Ethics committee of Children's hospital Zagreb approved the study protocol and decided that patient consent was not required.

## *Susceptibility testing*

The antimicrobial susceptibility to a wide range of antibiotics was determined by broth microdilution in Mueller-Hinton broth and 96 well microtiter plates according to CLSI guidelines [17]. Minimum inhibitory concentrations (MICs) were determined for imipenem and meropenem by agar dilution in the presence of sodium chloride (200 mM) for detection of OXA-58 and cloxacillin (200 mg/L) for detection of AmpC hyperproduction [18]. Combined disk test with EDTA was used for detection of metallo- $\beta$ -lactamases [19]. To assess the possible role of upregulated efflux in resistance, MIC of meropenem was determined in the presence of 12.5 $\mu$ M of an efflux pump inhibitor, carbonylcyanide-m-chlorophenylhydrazon CCCP [20].

The *A. baumannii* isolates were classified as multidrug-resistant (MDR), extensively drug-resistant (XDR) or pandrug-resistant (PDR) according to Magiorakos [21].

## *Detection of resistance genes*

PCR was used to detect the presence of the genes encoding KPC, MBLs of IMP, VIM and SIM series [22], *bla*<sub>OXA</sub> (*bla*<sub>OXA-51</sub>, *bla*<sub>OXA-23</sub>, *bla*<sub>OXA-24/40</sub>, *bla*<sub>OXA-58</sub>, *bla*<sub>OXA-143</sub>) [23] and *bla*<sub>ESBL</sub> (*bla*<sub>SHV</sub>, *bla*<sub>TEM</sub>, *bla*<sub>CTX-M</sub>, *bla*<sub>GES</sub> and *bla*<sub>PER-1</sub>) genes as previously described [24-28]. The amplicons of the selected representative isolates (2, 3, 7 and 8) were column purified (QIAquick PCR purification kit, Inel Medicinska tehnika, Zagreb) and subjected to sequencing in the Eurofin sequencing service with the same primers used for PCR in order to determine the identity of the enzyme. Sequence alignment analysis was done online by utilizing the BLAST Program. The genetic context of *bla*<sub>OXA-51</sub> and *bla*<sub>OXA-23</sub> genes was determined by PCR mapping with the primers for *ISAbal* combined with forward and reverse primers for *bla*<sub>OXA-51</sub> [29].

#### *Characterization of plasmids*

Conjugation experiments were performed using *Escherichia coli* J 53 resistant to sodium azide [30]. Since conjugation experiments did not work out the plasmid DNA was extracted and transferred to CaCl<sub>2</sub> treated *Acinetobacter baumannii* ATCC 17978 by transformation. Transformants were selected on MacConkey agar containing 10µg/ml imipenem [30]. Plasmid incompatibility groups were determined by PCR-based replicon typing (PBRT) according to Bertini et al [31].

#### *Molecular typing of isolates*

Sequence groups (1-3) corresponding to ICL (International Clonal Lineage) I-III were determined by multiplex PCR as described previously [32]. Nine isolates (1, 2, 3, 4, 5, 6, 9, 10 and 11) were subjected to molecular typing by rep-PCR as described previously. All data were entered in the DiversiLab software system. Cut-off value of 97% was used to define a clone [33].

Four isolates (1, 3, 6 and 9) were also genotyped by MLST according to protocols of the

Oxford scheme (*gltA*, *gyrB*, *gdhB*, *recA*, *cpn60*, *gpi* and *rpoD*). Details of the MLST scheme including amplification and sequencing are available at pubMLST web site (<https://pubmlst.org/abaumannii/>).

## Results

### *Antimicrobial susceptibility testing and phenotypic detection of beta-lactamases*

All isolates were resistant to piperacillin/tazobactam, ceftazidime, cefotaxime, ceftriaxone, cefepime, imipenem, meropenem, gentamicin and ciprofloxacin as shown in Table 1. Moderate resistance rates were observed for ampicillin/sulbactam (67%) and tigecycline (42%). The isolates were uniformly susceptible to colistin. They were all classified as XDR according to Magiorakos, as they were susceptible only to colistin and tigecycline (Table 1). Colistin was used to treat the infections caused by resistant *A. baumannii* with successful outcome in all patients.

The addition of either sodium chloride or cloxacillin did not lower the MICs of carbapenems indicating the lack of OXA-58 and no hyperproduction of chromosomal AmpC  $\beta$ -lactamase. CCCP did not decrease the carbapenem MICs either, excluding the effect of hyperexpression of efflux pumps on carbapenem MICs. The production of carbapenemase was identified by CIM test in all isolates. All isolates demonstrated enlargement of the inhibition zone around imipenem and meropenem disks supplemented with EDTA, ranging from 10 to 21 mm, indicating the production of an MBL.

### *Molecular detection of resistance genes*

PCR revealed OXA-24-like CHDL in nine and OXA-23-like CHDL in three isolates (Table 1). Sequencing of the selected *bla*<sub>OXA-24</sub> amplicons (2, 3, 7 and 8) revealed OXA-72 allelic variant, *bla*<sub>OXA-51</sub> genes and *bla*<sub>OXA-23</sub> genes were preceded by *ISAbal*. PCR for the common MBLs and ESBLs found in *A. baumannii* was negative.

### *Characterization of plasmids*

Attempts to transfer imipenem resistance by conjugation or transformation were unsuccessful indicating chromosomal location of *bla*<sub>OXA-23</sub> gene. The plasmids extracted from isolates positive for OXA-23 belonged to Inc group 2 encoding Aci2 replicasa gene.

### *Molecular typing of isolates*

All isolates belonged to SG 1 corresponding to ICL II. Rep-PCR performed on nine isolates identified one large cluster with six isolates which contained subtypes with highly related isolates (Fig. 1). Three isolates were singletons. Two isolates (3 and 9) positive for OXA-24-like were found to belong to ST492 (Table 1) whereas two isolates (1 and 6) were assigned to ST1926, a new multilocus sequence type with the pattern (1/3/3/3/2/96/3).

### **Discussion**

The study found OXA-24-like  $\beta$ -lactamase to be the dominant CHDL among children's *A. baumannii* isolates which is in concordance with the previous studies in Croatia [10-13]. OXA-24-like CHDL is widespread in Iberian Peninsula [34], USA [35], Czech Republic [36] and Bulgaria [37] and was recently reported in our neighbouring countries Bosnia and Herzegovina [38] and Serbia [39]. Representative isolates were positive for OXA-72 which is the only allelic variant of OXA-24-like, reported in Croatia so far.

OXA-23 was found in three isolates. This type of CHDL is widespread and reported all over the world [40-42]. It was reported previously from two hospital centers in Zagreb [12] in the multicenter study conducted in 2009-2010 and was previously also found in a nursing home in Zagreb, Croatia [13] and in environment [15]. The isolates carrying *bla*<sub>OXA-23</sub> gene were found to exhibit similar resistance patterns as those harbouring *bla*<sub>OXA-24/40</sub>-like genes. The majority of studies proved plasmid location of OXA-23 gene, but in our study conjugation



experiments failed. However, the OXA-23 positive isolate was found to possess the plasmid belonging to Inc 6 group by PBRT.

The diffusion of OXA-24-like producing isolates among children is in contrast with recent global dissemination of OXA-23 reported all over the world. In contrast to the previous studies in which emergence of OXA-24-like positive isolates was monoclonal, in this study we found considerable genetic diversity of the isolates. False positive MBL testing in CHDL positive isolates can be due to the fact that oxacillinase can be converted to a less active state in the presence of EDTA leading to the augmentation of the inhibition zone [43]. The predominance of OXA-23 and OXA-24 could be attributable to better hydrolysis of carbapenem substrates compared to OXA-58 which provides selective advantage in antibiotic rich environment. Two isolates positive for OXA-24-like were found to belong to ST492 which was never reported in Croatia before. Previous studies in Croatia found the predominance of ST487, ST637 and ST195 [13, 44]. A new strain type is also reported in this study. The ST1926 is closely related to ST195 (only differing in *recA*). ST195 is been known to be present in different (east) Asian countries (45).

None of the sulbactam/ampicillin-resistant isolates carried the *bla*<sub>TEM-1</sub> gene, suggesting that in *A. baumannii* resistance to sulbactam may rely on additional mechanisms, besides TEM-1 overexpression although this was the most important mechanism as reported previously [46]. The strength of the present study is the detailed molecular analysis of resistance mechanism while the few number of the strains and their relatedness are a weakness. This investigation will give rise to future multicenter studies to obtain insight on molecular epidemiology of paediatric *A. baumannii* isolates from different geographic regions in Croatia.

This is the first report of carbapenem resistant *A. baumannii* in children population in Croatia.

#### **Disclosure Statement**

The authors have no conflicts of interest to declare.

## Funding

University of Zagreb support (2018) “Mechanisms of colistin resistance in Gram-negative bacteria”

## Author contributions

Isolate collecting: ALG, MK

Laboratory work: ALG, MK, MŽ, JL, GZ, BB

Critical review: AG

Writing the manuscript: ALG, MK, BB

## References

1. Coelho I, Woodford N, Turton J, Livermore DM. Multiresistant *Acinetobacter* in the UK: how big a threat? *J Hosp Infect.* 2004;58:167-9.
2. Brown S, Amyes S. OXA  $\beta$ -lactamase in *Acinetobacter*: the story so far. *J Antimicrob Chemother.* 2006;57:1-3.
3. Cornaglia G, Riccio ML, Mazzariol A, Lauretti L, Fontana R, Rossolini GM. Appearance of IMP-1 metallo- $\beta$ -lactamase in Europe. *Lancet* 1999;353:899-900.
4. Hrabak J, Stolobova M, Studentova V, Fridrichova M, Chudackova E, Zemlickova H. NDM-1 producing *Acinetobacter baumannii* isolated from a patient repatriated to the Czech Republic from Egypt, July 2011. *Euro Surveill.* 2012;17(11):325-333.
5. Perilli M, Pelegrini C, Calenza G, Segatore B, Amicosante G. First report from Italy of *bla*<sub>VIM-1</sub> and *bla*<sub>TEM-1</sub> genes in *Pseudomonas putida* and *Acinetobacter baumannii* isolated from wastewater. *J Chemother.* 2011;23:181-2.
6. Robledo IE, Aquino EE, Sante MI, Santana JL, Oterko DM, Leon CF, Vazquez GJ. Detection of KPC in *Acinetobacter* spp in Puerto Rico. *Antimicrob Agents Chemother.* 2010;43:1354-1357.
7. Poirel L, Nordmann P. Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clin Microb Infect.* 2006;12:826-36.

8. Goić-Barišić I, Bedenić B, Tonkić M, Katić S, Kalenić S, Punda-Polić V. Molecular characterisation of carbapenem resistant *Acinetobacter baumannii* in different Intensive Care Units in University Hospital Split, Croatia J Chemother. 2007;19(4):462-4.
9. Goić-Barišić I, Bedenić B, Tonkić M, Novak A, Katić S, Kalenić S, Punda-Polić V, Towner KJ. Occurrence of OXA-107 and IS*AbaI* in carbapenem-resistant isolates of *Acinetobacter baumannii* from Croatia. J Clin Microbiol. 2009;47(10):3348-9.
10. Franolić-Kukina I, Bedenić B, Budimir A, Herljević Z, Vraneš J, Higgins P. Clonal spread of carbapenem-resistant OXA-72 positive *Acinetobacter baumannii* in a Croatian university hospital. Int J Infect Dis. 2011;15:e706-e709.
11. Goić-Barišić I, Towner, KJ, Kovačić A, Šiško-Kraljević K, Tonkić M, Novak A, Punda-Polić V. Outbreak in Croatia caused by a new carbapenem-resistant clone of *Acinetobacter baumannii* producing OXA-72 carbapenemase. J Hospit Infect. 2011;77(4):368-9.
12. Vranić-Ladavac M, Bedenić B, Minandri F, Ištok M, Bošnjak Z, Frančula-Zaninović S, Ladavac R, Visca P. Carbapenem resistance and acquired class D  $\beta$ -lactamases in *Acinetobacter baumannii* from Croatia 2009-2010. Eur J Clin Microbiol Infect Dis. 2014;33(3):471-8.
13. Bedenić B, Beader N, Godič-Torkar K, Vranić-Ladavac M, Luxner J, Veir Z, Grisold AJ, Zarfel G. Nursing home as reservoir of carbapenem-resistant *Acinetobacter baumannii*. Microb Drug Resist. 2015;21(3):270-8.
14. Hrenović J, Durn G, Goić-Barišić I, Kovačić A. Occurrence of an environmental *Acinetobacter baumannii* strain similar to a clinical isolate in paleosol from Croatia. Appl Environ Microbiol. 2014;80(9):2860-6.

15. Hrenović J, Goić-Barišić I, Kazazic S , Kovačić A, Ganjto M, Tonkić M. Carbapenem-resistant isolates of *Acinetobacter baumannii* in a municipal wastewater treatment plant, Croatia, 2014. Euro Surveill. 2016;21(15):pii=30195.
16. Hrenović J, Durn G, Šeruga-Musić M, Dekić S, Troskot-Čorbić T, Škorić D. Extensively and multi drug-resistant *Acinetobacter baumannii* recovered from technosol at a dump site in Croatia. Sci Total Environ. 2017;607-608:1049-55.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement, M100-S18. Wayne, PA: CLSI; 2016.
18. Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, Bethimouti K, Maniatis AN, Legakis NJ, Tsakris A. Outbreak of multiple clones of imipenem-resistant *Acinetobacter baumannii* isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother. 2006;57:557-561.
19. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA-double-disk synergy test for differentiating metallo- $\beta$ -lactamase-producing isolates of *Pseudomonas* spp. and *Acinetobacter* spp. J Clin Microbiol. 2003;41:4623-9.
20. Pournaras, S, Maniati M, Spanakis N, Ikonomidis A, Tassios PT, Tsakris A, Legakis NJ, Maniatis AN. Spread of efflux pump-overexpressing, non-metallo- $\beta$ -lactamase-producing, meropenem-resistant but ceftazidime-susceptible *Pseudomonas aeruginosa* in a region with *bla*<sub>VIM</sub> endemicity. J Antimicrob Chemother. 2005;56:761-4.
21. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.

22. Poirel L, Walsh TR, Cuveiller V, Nordman P. Multiplex PCR for detection of acquired carbapenemases genes. *Diagn Microbiol Infect Dis.* 2011;70:119-125.
23. Woodford N, Ellington MJ, Coelho J, Turton J, Ward ME, Brown S, Amyes SG, Livermore DM. Multiplex PCR for genes encoding prevalent OXA carbapenemases. *Int. J Antimicrob Agents.* 2006;27:351-3.
24. Arlet G, Brami G, Deere D, Flippo A, Gaillot O, Lagrange PH, Philippon A. Molecular characterization by PCR restriction fragment polymorphism of TEM  $\beta$ -lactamases. *FEMS Microbiol Lett.* 1995;134:203-8.
25. Nüesch-Inderbilen MT, Hächler H, Kayser FH. Detection of genes coding for extended-spectrum SHV  $\beta$ -lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. *Eur J Clin Microbiol Infect Dis.* 1996;15:398-402.
26. Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D et al. Community and hospital spread of *Escherichia coli* producing CTX-M extended-spectrum  $\beta$ -lactamases in the UK. *J Antimicrob Chemother.* 2004;54:735-43.
27. Pagani L, Mantengoli E, Migliavacca R, Nucleo E, Pollini S, Spalla M et al. Multifocal detection of multidrug-resistant *Pseudomonas aeruginosa* producing PER-1 extended-spectrum  $\beta$ -lactamase in Northern Italy. *J Clin Microbiol.* 2004;42:2523-9.
28. Bonnin RA, Nordmann P, Potron A, Lecuyer H, Zahar JR, Poirel L. Carbapenem hydrolyzing GES-type extended-spectrum beta-lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2011;55:349-54.
29. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, Pitt TL. The role of IS*Aba1* in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS Microbiol Lett.* 2006;258:72-7.

30. Elwell LP, Falkow S. The characterization of R plasmids and the detection of plasmid-specified genes. In: Lorian V, ed. *Antibiotics in Laboratory Medicine*. 2<sup>nd</sup> edn. Baltimore MD: Williams and Wilkins, 1986: 683-721.
31. Bertini A, Poirel L, Mugnier P, Villa J, Nordman P, Caratoli A. Characterization and PCR-based replicon typing of resistance plasmids in *Acinetobacter baumannii*. *Antimicrobial Agents Chemother*. 2010;54:4168-77.
32. Turton JF, Gabriel SN, Valderrey C, Kaufmann ME, Pitt TL. Use of sequence based typing and multiplex PCR to identify clonal lineages of outbreak strains of *Acinetobacter baumannii*. *Clin Microbiol Infect*. 2007;13:807-15.
33. Overdeest S, Willemsen C, Elberts M, Verhulst P, Rijnsburger J, Savelkoulnd A, Kluytmans JW. Evaluation of the DiversiLab Typing Method in a Multicenter Study: Assessing Horizontal Spread of Highly Resistant Gram-Negative Rods. *J Clin Microbiol*. 2011;49:3551-3554.
34. Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D  $\beta$ -lactamase with carbapenemase activity in an *Acinetobacter baumannii* clinical strain. *Antimicrob Agents Chemother*. 2000;44:1556-61.
35. Lolans K, Rice TW, Munoz-Price S, Quinn JP. Multicity outbreaks of carbapenem-resistant *Acinetobacter baumannii* isolates producing the carbapenamase OXA-40. *Antimicrob Agents Chemother*. 2006;50:2941-5.
36. Nemec A, Krizova L, Maixnerova M, Diancourt L, van der Reijden TJ, Brisse S, van den Broek P, Dijkshoorn L. Emergence of carbapenem resistance in *Acinetobacter baumannii* in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II. *J Antimicrob Chemother*. 2008;62(3):484-9.

37. Todorova B, Velinov T, Ivanov I, Dobрева E, Kantardijev T. First detection of OXA-24 carbapenemase-producing *Acinetobacter baumannii* in Bulgaria. *World J Microbiol Biotechnol.* 2014;30(4):1427-30.
38. Petrović T, Uzunović S, Barišić I, Luxner J, Grisold A, Zarfel G, Ibrahimagić A, Jakovac S, Slaćanac D, Bedenić B. Arrival of carbapenem-hydrolyzing-oxacillinases in *Acinetobacter baumannii* in Bosnia and Herzegovina. *Infect Genet Evol.* 2018;192-198. doi: 10.1016/j.meegid.2017.12.021.
39. Dortet, L, BonNin RA, Bernbeu S, Escaut L, Vittecoq D, Girlich D, et al. First occurrence of OXA-72-producing *Acinetobacter baumannii* in Serbia. *Antimicrob Agents Chemother.* 2016;23:60(10):5724-30.
40. Towner KJ, Levi K, Vlassiadi M. Genetic diversity of carbapenem-resistant isolates of *Acinetobacter baumannii* in Europe. *Clin Microbiol Infect.* 2007;14:161-7.
41. Coelho JM, Turton JF, Kaufmann M.E, Glover J, Woodford N, Warner M, Palepou MF, Pike R, Pittm TL. Occurrence of carbapenem-resistant *Acinetobacter baumannii* clones at multiple hospitals in London and Southeast England. *J Clin Microbiol.* 2006;44(10):3623-3627.
42. Zong Z, Lu X, Valenzuela JK, Partridge SR, Iredell J. An outbreak of carbapenem-resistant *Acinetobacter baumannii* producing OXA-23  $\beta$ -lactamase. *Int J Antimicrob Agents.* 2008;31(1):50-4.
43. Vilalon P, Valdezeteб S, Medina-Pascual MJ, Curasco G, Vindel A, Saez-Nieto JA. Epidemiology of the *Acinetobacter*-derived cephalosporinase, carbapenem-hydrolyzing oxacillinase and metallo- $\beta$ -lactamase genes, and of common insertion sequences, in epidemic clones of *Acinetobacter baumannii*. *J Antimicrob Chemother.* 2011;68:550-3.
44. Ladavac R, Bedenić B, Vranić-Ladavac M, Barišič N, Karčić N, Pompe K, Ferenčić A, Stojanović A, Seifer H, Katić S, Higgins PG. Emergence of different *Acinetobacter*

*baumannii* clones in a Croatian hospital and correlation with antibiotic susceptibility. J Glob Antimicrob Resist. 2017;10:213-218. doi: 10.1016

45. Junyan Qu, Yu Du, Rujia Yu, and Xiaoju Lü, "The First Outbreak Caused by *Acinetobacter baumannii* ST208 and ST195 in China," BioMed Research International, vol. 2016, Article ID 9254907, 6 pages, 2016. <https://doi.org/10.1155/2016/9254907>.


46. Krizova L, Poirel L, Nordmann P, Nemeč A. TEM-1  $\beta$ -lactamase as a source of resistance to sulbactam in clinical strains of *Acinetobacter baumannii*. J Antimicrob Chemother. 2013;68:2786-91.

Table 1. Antibiotic susceptibility, genotypes and beta-lactamase content of *A. baumannii* isolates from children

Fig.1. Molecular typing of isolates



Diversilab v3.6  
PC  
#1132



| Ordinal number | Date of isolation (month/year) | Specimen        | Protocol number | Hospital ward | TZP  | SAM | CAZ  | CTX  | CRO  | FEP  | IMI | MEM  | GM   | CIP  | TIG | COL | SG/Rep-PCR cluster/ST | BL              |
|----------------|--------------------------------|-----------------|-----------------|---------------|------|-----|------|------|------|------|-----|------|------|------|-----|-----|-----------------------|-----------------|
| 1              | 11/2017                        | Burn swab       | 22742           | ICU           | >128 | 16  | >128 | >128 | >128 | 32   | 64  | 64   | >128 | >128 | 2   | 1   | SG 1/S ST492          | Isaba 1/OXA-23  |
| 2              | 11/2017                        | Wound swab      | 22698           | ortopedics    | >128 | 32  | >128 | >128 | >128 | 64   | 64  | >128 | >128 | >128 | 1   | 1   | SG1/A4 ST-1926        | OXA-24          |
| 3              | 09/2017                        | Burn swab       | 17180           | Burn unit     | >128 | 16  | >128 | >128 | >128 | 32   | 64  | >128 | >128 | >128 | 2   | 1   | SG1/A1 ST492          | OXA-24          |
| 4.             | 07/2017                        | Stomach fluid   | 18255           | paediatrics   | >128 | 64  | >128 | >128 | >128 | 64   | 64  | >128 | >128 | >128 | 4   | 1   | SG1/S                 | OXA-24          |
| 5.             | 04/2017                        | Blood culture   | 8100            | ICU           | >128 | 32  | >128 | >128 | >128 | 128  | 32  | >128 | >128 | >128 | 2   | 0.5 | SG1/A2                | OXA-24          |
| 6.             | 06/2017                        | Wound swab      | 12241           | ICU           | >128 | 16  | >128 | >128 | >128 | 128  | 64  | >128 | >128 | >128 | 2   | 1   | SG1/S 1926            | OXA-24          |
| 7.             | 08/2016                        | IV catheter tip | 18285           | ICU           | >128 | 16  | >128 | >128 | >128 | 128  | 64  | >128 | >128 | >128 | 4   | 1   | SG1                   | OXA-24          |
| 8.             | 12/2016                        | Burn swab       | 27097           | ICU           | >128 | 64  | >128 | >128 | >128 | >128 | 64  | >128 | >128 | >128 | 2   | 0.5 | SG1                   | OXA-24          |
| 9              | 08/2016                        | Blood culture   | 17476           | ICU           | >128 | 64  | >128 | >128 | >128 | 32   | 64  | >128 | >128 | >128 | 4   | 1   | SG1/A4, 1926          | OXA-24          |
| 10             | 10/2017                        | Wound swab      | 18440           | surger y      | >128 | 32  | >128 | >128 | >128 | 64   | 64  | >128 | >128 | >128 | 2   | 0.5 | SG1/A1                | OXA-24          |
| 11             | 03/2018                        | Rectum swab     | 5712            | ICU           | >128 | 64  | >128 | >128 | >128 | >128 | 64  | >128 | >128 | >128 | 4   | 0.5 | SG1/A3                | ISAb a 1/OXA-23 |
| 12             | 07/2017                        | Burn swab       | 14900           | ICU           | >128 | 64  | >128 | >128 | >128 | >128 | 64  | >128 | >128 | >128 | 4   | 0.5 | SG1                   | ISAb a 1/OXA-23 |

Table 1. Antibiotic susceptibility,  $\beta$ -lactamase production and genotypes of *A. baumannii* isolates from children.

Abbreviations; TZP-piperacillin/tazobactam; SAM; sulbactam/ampicillin; CAZ-ceftazidime; CRO-ceftriaxone; FEP-cefepime;IMI-imipenem; MEM-meropenem; GM-gentamicin; CIP-ciprofloxacin; TIG-tigecycline; COL-colistin; ST-sequence type SG-sequence group; BL: beta-lactamase content: ICU-intensive care unit

